A multidisciplinary panel of experts provides an overview of the economic burden of HIV and the role of pre-exposure prophylaxis (PrEP) in preventing HIV transmission. Ian Frank, MD and Jeffrey ...
In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...
A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...
HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...
LA CAB for PrEP shows high effectiveness and persistence among Black cisgender and transgender women in the United States.
Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...
Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...
The Centers for Disease Control and Prevention (CDC) has updated its guidance to recommend that doctors more readily prescribe and inform patients about medicine that prevents HIV called pre-exposure ...
The Global Fund has committed an additional Sh256 million($2 million) to support Kenya’s rollout of the long-acting HIV preventioninjection, Lenacapavir, officials announced during the national launch ...
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results